FDA Generics Rule: Relevance To Pending NDAs May Need Clarification – Troy
This article was originally published in The Tan Sheet
Executive Summary
Patent information in currently pending NDAs may not fall under the jurisdiction of FDA's final rule on generic drugs
You may also be interested in...
FDA Adds Patent Declaration Forms For Innovators To Generic Final Rule
Patent declaration forms must be used for Orange Book submission of patent information under FDA's generic reform final rule
WCC Plan B OTC Marketing Partnership Sought Pending Switch Approval
Women's Capital Corporation "is in discussions with a number of potential strategic marketers" to sell an OTC version of its Plan B emergency contraceptive pending approval of the firm's April 21 switch application
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC